Extracellular Vesicle Proteins Associated with Systemic Vascular Events Correlate with Heart Failure: An Observational Study in a Dyspnoea Cohort

Background SerpinF2, SerpinG1, CystatinC and CD14 are involved in inflammatory processes and plasma extracellular vesicle (EV) -levels of these proteins have been reported to be associated with systemic vascular events. Evidence is accumulating that inflammatory processes may play a pivotal role both in systemic vascular events and in heart failure. Therefore, we studied the association between plasma extracellular vesicle SerpinF2-, SerpinG1-, CystatinC and CD14-levels and the occurrence of acute heart failure in patients. Methods and Result Extracellular vesicle protein levels of SerpinG1, SerpinF2, CystatinC and CD14 were measured in an observational study of 404 subjects presenting with dysponea at the emergency department (4B-cohort). Plasma extracellular vesicles were precipitated in a total extracellular vesicles (TEX)-fraction and in separate LDL- and HDL-subfractions. Extracellular vesicle protein levels were measured with a quantitative immune assay in all 3 precipitates. Out of 404 subjects, 141 (35%) were diagnosed with acutely decompensated heart failure. After correction for confounders (including comorbidities and medications), levels of CD14 in the HDL-fraction (OR 1.53, p = 0.01), SerpinF2 in the TEX-and LDL-fraction (ORs respectively 0.71 and 0.65, p<0.05) and SerpinG1 in the TEX-fraction (OR 1.55, p = 0.004) were statistically significantly related to heart failure. Furthermore, extracellular vesicle CD14- and SerpinF2-levels were significantly higher in heart failure patients with preserved ejection fraction than in those with reduced ejection fraction. Conclusion Extracellular vesicle levels of CD14, SerpinG1 and SerpinF2 are associated with the occurrence of heart failure in subjects suspected for acute heart failure, suggesting common underlying pathophysiological mechanisms for heart failure and vascular events.

[1]  V. Gross,et al.  Inflammatory mediators in chronic inflammatory bowel diseases , 1991, Klinische Wochenschrift.

[2]  G. Ma,et al.  Intermediate monocytes lead to enhanced myocardial remodelling in STEMI patients with diabetes. , 2015, International heart journal.

[3]  V. Dharnidharka,et al.  Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  S. Hazen,et al.  Prognostic comparison of different sensitivity cardiac troponin assays in stable heart failure. , 2015, The American journal of medicine.

[5]  Pedro Mejia,et al.  C1 inhibitor, a multi-functional serine protease inhibitor , 2010, Thrombosis and Haemostasis.

[6]  B. Brenner,et al.  Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells , 2008, Thrombosis and Haemostasis.

[7]  A. Hara,et al.  Lack of α2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction , 2002 .

[8]  C. O'connor,et al.  Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. , 2012, American heart journal.

[9]  D. Siscovick,et al.  Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.

[10]  M. Schuliga.  The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease , 2015, Mediators of inflammation.

[11]  A. Hara,et al.  Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. , 2002, Blood.

[12]  F. Visseren,et al.  For peer review only Microvesicle protein levels are related to brain atrophy and cerebral white matter lesions in patients with manifest vascular disease: the SMART-MR study , 2013 .

[13]  S. Massry,et al.  Reduced alpha-2-antiplasmin levels in the nephrotic syndrome. , 1985, Nephron.

[14]  G. Nickenig,et al.  Circulating CD 31 1 / Annexin V 1 microparticles correlate with cardiovascular outcomes , 2011 .

[15]  D. Levy,et al.  Cardiac Dysfunction and Noncardiac Dysfunction as Precursors of Heart Failure With Reduced and Preserved Ejection Fraction in the Community , 2011, Circulation.

[16]  M. Goumans,et al.  Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction , 2008, Circulation research.

[17]  R. Morfin,et al.  Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. , 1970, Journal of lipid research.

[18]  Masaaki Konishi,et al.  Prognostic value of endothelial microparticles in patients with heart failure , 2010, European journal of heart failure.

[19]  A. Maisel,et al.  State-of-the-Art PaperNatriuretic Peptides , 2007 .

[20]  D. Muthu,et al.  Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure , 2009 .

[21]  P. Poole‐Wilson,et al.  Coronary artery disease as the cause of incident heart failure in the population. , 2001, European heart journal.

[22]  Stephan von Haehling,et al.  Inflammatory mediators in chronic heart failure: an overview , 2004, Heart.

[23]  P. Stein,et al.  Risk of venous thromboembolism in patients hospitalized with heart failure. , 2006, The American journal of cardiology.

[24]  Z. Giricz,et al.  Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison of Ultracentrifugation and Size Exclusion Chromatography Methods , 2015, PloS one.

[25]  P. Ponikowski,et al.  Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). , 2013, JACC. Heart failure.

[26]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[27]  R. Vasan,et al.  Association of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham Heart Study. , 2014, European heart journal.

[28]  Arno W Hoes,et al.  Serum extracellular vesicle protein levels are associated with acute coronary syndrome , 2013, European heart journal. Acute cardiovascular care.

[29]  A. Berezin,et al.  Circulating Endothelial-Derived Apoptotic Microparticles in the Patients with Ischemic Symptomatic Chronic Heart Failure: Relevance of Pro-Inflammatory Activation and Outcomes , 2014, International cardiovascular research journal.

[30]  L. Kappelle,et al.  Extracellular vesicle protein levels are related to brain atrophy and cerebral white matter lesions in patients with manifest vascular disease: the SMART-MR study , 2014, BMJ Open.

[31]  P. Poole‐Wilson,et al.  Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. , 1997, The American journal of cardiology.

[32]  G. Pasterkamp,et al.  Innate immune signaling in cardiac ischemia , 2011, Nature Reviews Cardiology.

[33]  C. Watson,et al.  Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of M2 macrophage activation in disease pathogenesis. , 2015, Journal of cardiac failure.

[34]  H. Ogawa,et al.  Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. , 2009, Journal of the American College of Cardiology.

[35]  Gerard Pasterkamp,et al.  Targeted Deletion of Nuclear Factor &kgr;B p50 Enhances Cardiac Remodeling and Dysfunction Following Myocardial Infarction , 2009, Circulation research.

[36]  G. Cervellin,et al.  Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial. , 2014, The American journal of emergency medicine.

[37]  G. Pasterkamp,et al.  Plasma extracellular vesicle protein content for diagnosis and prognosis of global cardiovascular disease , 2013, Netherlands Heart Journal.

[38]  Andrew F. Hill,et al.  Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles , 2014, Journal of extracellular vesicles.

[39]  Helmut Baumgartner,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, European journal of heart failure.

[40]  A. Low,et al.  Iron deficiency in a multi‐ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis , 2014, European journal of heart failure.

[41]  B. Ylstra,et al.  Endogenous C1-inhibitor production and expression in the heart after acute myocardial infarction. , 2016, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[42]  G. Vilahur,et al.  Thrombosis formation on atherosclerotic lesions and plaque rupture , 2014, Journal of internal medicine.

[43]  Da-Wei Liao,et al.  Circulating TNFR1 exosome-like vesicles partition with the LDL fraction of human plasma. , 2008, Biochemical and biophysical research communications.

[44]  L. Kappelle,et al.  Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. , 2013, International journal of cardiology.

[45]  Chi‐Hang Lee,et al.  Ethnicity Modifies Associations between Cardiovascular Risk Factors and Disease Severity in Parallel Dutch and Singapore Coronary Cohorts , 2015, PloS one.

[46]  A. Berezin,et al.  The Association of Subclinical Hypothyroidism and Pattern of Circulating Endothelial-Derived Microparticles Among Chronic Heart Failure Patients , 2015, Research in cardiovascular medicine.

[47]  S. Fernandes,et al.  The effect of C1 inhibitor on myocardial ischemia and reperfusion injury. , 2013, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[48]  A. Maisel,et al.  Natriuretic peptides. , 2007, Journal of the American College of Cardiology.

[49]  C. Théry,et al.  Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. , 2014, Annual review of cell and developmental biology.

[50]  G. Schmitz,et al.  C(-260)-->T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. , 1999, Circulation.

[51]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[52]  U. Janssens,et al.  CD14 gene -260 C/T polymorphism is associated with chronic heart failure. , 2005, European journal of internal medicine.

[53]  Critical residues involved in Toll-like receptor 4 activation by cationic lipid nanocarriers are not located at the lipopolysaccharide-binding interface , 2015, Cellular and Molecular Life Sciences.